Loading cancer entity…
Loading cancer entity…
Clinical trials
113 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00100880 | Lenalidomide in Treating Young Patients With Recurrent, Progressive, or Refractory CNS Tumors | completed | Phase 1 | 45 | National Cancer Institute (NCI)NIH | 1 | Sep 30, 2013 | clinicaltrials |
| NCT00994500 | Vorinostat and Bortezomib in Treating Young Patients With Refractory or Recurrent Solid Tumors, Including Central Nervous System Tumors and Lymphoma | completed | Phase 1 | 20 | National Cancer Institute (NCI)NIH | 1 | Jul 2, 2013 | clinicaltrials |
| NCT00004078 | Irinotecan in Treating Children With Refractory Solid Tumors | completed | Phase 2 | 181 | Children's Oncology GroupNETWORK | 1 | Jun 14, 2013 | clinicaltrials |
| NCT01076530 | Vorinostat and Temozolomide in Treating Young Patients With Relapsed or Refractory Primary Brain Tumors or Spinal Cord Tumors | completed | Phase 1 | 27 | National Cancer Institute (NCI)NIH | 2 | May 3, 2013 | clinicaltrials |
| NCT00030498 | Erlotinib in Treating Patients With Solid Tumors and Liver or Kidney Dysfunction | completed | Phase 1 | 75 | National Cancer Institute (NCI)NIH | 1 | Jan 16, 2013 | clinicaltrials |
| NCT00110032 | Positron Emission Tomography Using Fluorine F 18 EF5 to Find Oxygen in Tumor Cells of Patients Who Are Undergoing Surgery or Biopsy for Newly Diagnosed Brain Tumors | terminated | Phase 1 | 46 | National Cancer Institute (NCI)NIH | 1 | Jan 16, 2013 | clinicaltrials |
| NCT00430079 | Use of EF5 to Measure the Oxygen Level in Tumor Cells of Patients Undergoing Surgery or Biopsy for Newly Diagnosed Supratentorial Malignant Glioma | terminated | N/A | 48 | National Cancer Institute (NCI)NIH | 1 | Jan 16, 2013 | clinicaltrials |
| NCT00389090 | A Phase II Study of Temozolomide and O6-Benzylguanine (O6-BG) in Patients With Temozolomide-Resistant Anaplastic Glioma | terminated | Phase 2 | 32 | Keryx / AOI Pharmaceuticals, Inc.INDUSTRY | 1 | Feb 9, 2012 | clinicaltrials |
| NCT00165360 | Prolonged Daily Temozolomide for Low-Grade Glioma | completed | Phase 2 | 46 | Dana-Farber Cancer InstituteOTHER | 1 | Nov 2, 2009 | clinicaltrials |
| NCT00591058 | Safety and Dose-Finding Study of TM-601 in Adults With Recurrent Malignant Glioma | unknown | Phase 1 | 36 | TransMolecularINDUSTRY | 1 | Jul 17, 2009 | clinicaltrials |
| NCT00683761 | A Study of 131I-TM601 in Adults With Recurrent Malignant Glioma | unknown | Phase 1 / Phase 2 | 64 | TransMolecularINDUSTRY | 1 | Jul 17, 2009 | clinicaltrials |
| NCT00080054 | A Study of Motexafin Gadolinium and Temozolomide for the Treatment of Malignant Gliomas | completed | Phase 1 | 24 | Pharmacyclics LLC.INDUSTRY | 1 | Apr 3, 2009 | clinicaltrials |
| NCT00717210 | Randomized Phase III Study of Sequential Radiochemotherapy of Anaplastic Glioma With PCV or Temozolomide(NOA-04) | completed | Phase 3 | 318 | Neuro-Oncology Working Group of the German Cancer SocietyNETWORK | 1 | Jul 17, 2008 | clinicaltrials |
Data updated 22 days agoSource updated Sep 30, 2013source: clinicaltrials